Rezolute says cash position totals $120 million, funds operations into mid-2028

Reuters2026/08/25 19:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Rezolute highlighted ersodetug, an IV monoclonal antibody targeting the insulin receptor for refractory hypoglycemia across hyperinsulinism types.
Phase 3 sunRIZE in congenital hyperinsulinism completed; open-label extension ongoing with 100% rollover and high retention.
Primary SMBG endpoint missed due to functional unblinding; multiple CGM measures showed clinically meaningful hypoglycemia reductions.
FDA review of analysis datasets ongoing; program update expected in 2H 2026, with topline data targeted for Q1 2027.
Cash position cited at USD 120 million, with runway to mid-2028; company framed a USD 1 billion-plus global market opportunity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Rezolute says cash position totals $120 million, funds operations into mid-2028

You may also like

Crypto prices